Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirnabine
- Development stage
- Unknown
- Lead developer
- Aquestive Therapeutics
- Modality
- Small Molecules
- Administration
- Ophthalmic, Oral
01
Overview
Pirnabine is a synthetic small molecule drug classified as a cannabinoid receptor ligand. It was originally developed for the treatment of glaucoma and has also been investigated in clinical trials for chronic idiopathic constipation. Pirnabine is structurally related to dibenzopyran compounds and may exert its effects by binding to cannabinoid receptors involved in gastrointestinal motility regulation, although its precise mechanism of action remains under investigation. The compound's IUPAC name is 3,6,6,9-tetramethyl-6H,7H,8H,9H,10H-cyclohexa[c]chromen-1-yl acetate.
- Other names
- pirnabinguanlib
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on pirnabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirnabine.